Exciting News from RDP Pharma AG
RDP Pharma AG to Present at the AACR Annual Meeting 2025
Romanshorn, Switzerland – April 14, 2025 – RDP Pharma AG is pleased to announce our participation at the AACR Annual Meeting 2025, at the McCormick Place Convention Center, Chicago, IL, USA
At this event, we will present three posters showcasing our drug candidate CP201, which is ready for phase 1 clinical trials in healthy volunteers. For more information on the posters, please see below.
Additionally, we will be there to discuss the latest developments of our unique, innovative Targeted Protein Degradation Platform PROMPT (Proteasomal Oral Monovalent Protein Targeting).
Our PromptDegrader™ pipeline includes:
- VS035 – First-in-Class, orally available, small molecule-based new chemical entity (NCE) HPV E7 Degrader
- c-MYC – MYC monovalent small molecule degrader-based NCE
- Two additional undisclosed targets
Poster #32
Title: Efficacy and tolerability of an enantiomer of Edelfosine (S-CP201) in pancreatic cancer PDX models as a single agent and in combination with approved drugs in clinical use
Session: Human and PDX Models 1
Date: 27th of April, 2025
Time: 2:00:00 PM – 5:00:00 PM
Location: Poster Section 2 – Board #11
Poster #4346
Title: Improved pharmacokinetic properties of the purified S-enantiomer of the alkylphospholipid Edelfosine compared to the racemic mixture: Potential orally available novel anticancer agent active against pancreatic cancer
Session: Pharmacokinetics and Pharmacodynamics of Cancer Therapeutics
Date: 29th of April, 2025
Time: 9:00:00 AM – 12:00:00 PM
Location: Poster Section 20 – Board #11
Poster #7278
Title: Non-clinical toxicity studies of S-CP201
Session: Novel In Vivo, In Vitro, and In Silico Models
Date: 30th April, 2025
Time: 9:00:00 AM -12:00:00 PM
Location: Poster Section 38 – Board #25
To set up a meeting to discuss our programs including our PROMPT platform please contact us!
Nathan Ehrlich, Business Development Manager – nathan.ehrlich@rdp-pharma.com
Dr. Michael Ahrweiler, Chief Development Officer/Founder – info@rdp-pharma.com
RDP Pharma AG to Present at the Ubiquitin & Friends Symposium 2025: Showcasing Breakthrough Research in HPV E7 Targeted Protein Degradation
Romanshorn, Switzerland – April 14, 2025 – RDP Pharma AG, a leading innovator in the field of targeted protein degradation, is excited to announce its participation in the upcoming 2025 Protein Degradation Symposium, held on May 8th and 9th, 2025. We will present a poster based on our breakthrough work in the development of a unique HPV E7-targeted protein degrader.
The research, titled „Unique HPV E7 Targeted Protein Degrader“, outlines RDP Pharma’s progress in advancing a novel therapeutic strategy for HPV-driven malignancies, including cervical cancer, one of the most prevalent cancers caused by human papillomavirus (HPV). The poster presentation will focus on our innovative work utilizing our proprietary PromptDegrader™ platform to design small-molecule degraders specifically targeting the high-risk HPV E7 oncoprotein.
Conference Details:
- Event: 2025 Protein Degradation Symposium
- Dates: May 8th and 9th, 2025
- Location: Vienna, Austria
- Attendees: Dr. Markus Müllner, CTO; Dr. Florian Kellner, Head of Biology; Dr. Antony Crisp, Head of Chemistry
- Presentation Title: „Unique HPV E7 Targeted Protein Degrader“
- Presenter: Dr. Florian Kellner, Head of Biology
“We are thrilled to be presenting our latest findings at this prestigious event and to showcase our innovative approach to targeting the HPV E7 oncoprotein,” said Dr. Markus Müllner, Chief Technology Officer at RDP Pharma AG.
20.02.2025 – RDP Pharma AG will be Attending the AACR 2025 Annual Meeting
Studies describing pre-clinical development of CP201, a purified enantiomer of Edelfosine, accepted for presentation at the American Association of Cancer Research (AACR) annual meeting in Chicago from April 25th – 30th, 2025
RDP Pharma AG (Switzerland), a private emerging biotechnology company is focused on developing novel therapeutics for cancer and other therapeutic areas. RDP is developing a novel protein degradation platform aimed at hard to drug targets such as c-MYC and viral regulatory proteins. Three AACR abstracts related to our legacy patented compound CP201, an enantiomer of the racemic drug Edelfosine were accepted for the AACR annual meeting. The Edelfosine drug candidate is initially targeted for Glioblastoma Multiforme, a brain cancer.
Abstract details will be disclosed on March 26th.
About RPD Pharma:
RDP Pharma AG was founded in 2019 by a group of industry veterans with decades of experience. Our team is comprised of highly accomplished entrepreneurs, and drug development experts. Our extensive experience ensures that the right questions are asked, the right experiments conducted, and the right clinical studies implemented to advance our programs. Our headquarter is in Romanshorn, Switzerland; and our chemistry and biology research operations are located Tulln, Austria, just outside of Vienna.
About CP201:
CP201 is an orally available enantiomer of the alkyllysophospholipid (ALP) Edelfosine. It is a synthetic etherlipid that is owned by RDP Pharma. Previously, Racemic Edelfosine, the parent compound of CP201, was tested in more than 1,300 cancer patients in phase 1 and 2 clinical trials conducted in the 1980s/1990s with encouraging signs of clinical activity in various cancers (e.g. lung cancer, brain cancer) and in patients with multiple sclerosis, whilst showing a favorable toxicity profile (mainly mild to moderate and reversible gastro-intestinal adverse events, e.g. nausea). A large number of patients have been administered edelfosine for over 2 years.
RDP has developed CP201, through extensive preclinical studies and it is ready for phase 1 clinical trials.
For more information please contact:
Dr. Michael Ahrweiler
Founder, Chief Development Officer
Amriswilerstrasse 51
CH-8590 Romanshorn
Switzerland
Tel. +41 71 466 33 68
info@rdp-pharma.com
www.rdp-pharma.com